
  
    
      
        Background_NNP
        During_IN positive_JJ inotropy_NN there_EX is_VBZ an_DT increase_NN in_IN ATP_NNP
        utilization_NN and_CC thus_RB myocardial_NN oxygen_NN consumption_NN related_VBN
        to_TO increased_VB cross-bridge_JJ cycling_NN and_CC calcium_NN handling_VBG [_NN 1_CD
        ]_NN ._. Heat_NNP measurements_NNS of_IN isolated_VBN heart_NN muscle_NN have_VBP
        assigned_VBN approximately_RB 50_CD %_NN of_IN total_JJ energy_NN consumption_NN to_TO
        cross-bridge_JJ cycling_NN and_CC 20_CD %_NN to_TO calcium_NN cycling_NN [_NN 2_CD ]_NN ._.
        However_RB ,_, recently_RB ,_, studies_NNS in_IN both_DT isolated_VBN hearts_NNS and_CC
        myocytes_NNS [_NN 3_CD 4_CD ]_NN ,_, examining_VBG the_DT energetic_JJ effects_NNS of_IN
        increasing_VBG inotropy_NN with_IN the_DT calcium_NN sensitizing_VBG agent_NN EMD_NNP
        57033_CD have_VBP suggested_VBN that_IN the_DT energetic_JJ cost_NN associated_VBN
        with_IN increasing_VBG inotropy_NN is_VBZ largely_RB related_VBN to_TO calcium_NN
        cycling_NN ._. In_IN these_DT studies_NNS EMD_NNP 57033_CD resulted_VBD in_IN only_RB small_JJ
        increases_NNS in_IN myocardial_NN oxygen_NN consumption_NN and_CC this_DT was_VBD
        felt_VBN related_VBN to_TO the_DT ability_NN of_IN EMD_NNP 57033_CD to_TO increase_VB
        inotropy_NN without_IN increasing_VBG calcium_NN cycling_NN (_( though_IN
        intracellular_NN calcium_NN was_VBD not_RB directly_RB measured_VBN )_) ._.
        Consistent_NNP with_IN this_DT Brandes_NNP et_CC al_NN [_NN 5_CD ]_NN have_VBP studied_VBN the_DT
        contribution_NN of_IN mechanical_JJ work_NN and_CC calcium_NN cycling_NN to_TO
        total_VB mitochondrial_NN ATP_NNP hydrolysis_NNS as_IN measured_VBN by_IN NADH_NNP
        levels_NNS using_VBG fluorescent_NN spectroscopy_NN of_IN rat_NN cardiac_JJ
        trabeculae_NN ._. They_PRP concluded_VBD that_IN there_EX was_VBD an_DT equal_JJ
        contribution_NN of_IN mechanical_JJ work_NN and_CC calcium_NN cycling_NN to_TO
        total_VB ATP_NNP hydrolysis_NNS ._. In_IN the_DT present_JJ study_NN ,_, we_PRP hypothesized_VBN
        that_DT energy_NN consumption_NN during_IN altered_VBN inotropy_NN is_VBZ largely_RB
        to_TO related_VBN calcium_NN handling_NN ._. To_TO study_VB this_DT we_PRP directly_RB
        measured_VBD developed_VBN pressures_NNS ,_, myocardial_NN oxygen_NN consumption_NN
        and_CC used_VBD a_DT newly_RB developed_VBN technique_NN to_TO measure_VB
        intracellular_NN calcium_NN in_IN perfused_JJ mouse_NN hearts_NNS with_IN the_DT
        calcium_NN sensitive_JJ fluorescent_NN dye_NN rhod-_NN 2_CD [_NN 6_CD 7_CD ]_NN during_IN
        calcium-induced_JJ inotropy_NN and_CC with_IN dobutamine_NN ._. In_IN addition_NN
        we_PRP studied_VBD the_DT perfused_JJ mouse_NN heart_NN ,_, as_IN the_DT ability_NN to_TO
        manipulate_VB the_DT murine_NN genome_NN will_MD likely_RB provide_VB important_JJ
        information_NN about_IN the_DT molecular_JJ determinants_NNS of_IN energy_NN
        consumption_NN in_IN the_DT heart_NN ._.
        The_DT mechanisms_NNS controlling_VBG calcium-induced_JJ inotropy_NN are_VBP
        probably_RB several_JJ fold_VB ,_, and_CC include_VBP activation_NN of_IN protein_NN
        kinase_NN C_NNP [_NN 8_CD ]_NN ,_, of_IN which_WDT several_JJ isoforms_NNS are_VBP calcium_NN
        dependent_JJ ._. Protein_NNP kinase_NN C_NNP decreases_NNS maximal_NN actomyosin_NN
        MgATPase_NNP activity_NN through_IN phosphorylation_NN of_IN troponin_NN I_PRP [_NN 9_CD
        ]_NN ._. This_DT would_MD be_VB predicted_VBN to_TO result_VB in_IN a_DT reduction_NN in_IN
        force_NN (_( or_CC developed_VBN pressure_NN )_) relative_JJ to_TO intracellular_NN
        calcium_NN resulting_VBG in_IN an_DT energetically_RB inefficient_JJ state_NN ._.
        Thus_RB ,_, we_PRP predicted_VBD that_IN high_JJ perfusate_NN calcium_NN positive_JJ
        inotropy_NN would_MD result_VB in_IN lower_JJR developed_JJ pressures_NNS relative_JJ
        to_TO both_DT intracellular_NN calcium_NN and_CC myocardial_NN oxygen_NN
        consumption_NN compared_VBN to_TO dobutamine_NN ,_, and_CC that_IN high_JJ perfusate_NN
        calcium_NN would_MD be_VB associated_VBN with_IN evidence_NN of_IN protein_NN kinase_NN
        C_NNP activation_NN ,_, though_IN not_RB dobutamine_NN ._.
      
      
        Results_NNS
        During_IN increases_NNS in_IN perfusate_NN calcium_NN (_( 1_CD ._. 5_LS -_: 3_CD ._. 5_CD mM_NN )_)
        there_EX were_VBD stepwise_NN increases_NNS in_IN developed_VBN pressure_NN ,_, and_CC
        developed_VBD pressures_NNS with_IN dobutamine_NN were_VBD significantly_RB
        higher_JJR than_IN perfusate_NN calcium_NN 3_CD ._. 5_CD mM_NN (_( Figure_NN 1_CD A_DT )_) ._. Peak_NNP
        systolic_JJ intracellular_NN calcium_NN increased_VBN minimally_RB between_IN
        1_CD ._. 5_CD and_CC 2_CD ._. 5_CD mM_NN despite_IN significant_JJ increases_NNS in_IN developed_VBN
        pressures_NNS indicating_VBG increased_VBN myofilament_NN responsiveness_NNS
        to_TO calcium_NN at_IN perfusate_NN calcium_NN 2_CD ._. 5_CD compared_VBN to_TO 1_CD ._. 5_CD mM_NN
        (_( Figure_NN 1_CD B_NNP )_) ._. Also_RB ,_, indicating_VBG reduced_VBN myofilament_NN
        responsiveness_NNS to_TO perfusate_NN calcium_NN 3_CD ._. 5_CD mM_NN compared_VBN to_TO
        dobutamine_NN ,_, levels_NNS of_IN peak_NN intracellular_NN calcium_NN were_VBD
        similar_JJ for_IN these_DT 2_CD interventions_NNS despite_IN higher_JJR developed_JJ
        pressure_NN with_IN dobutamine_NN ._. Increases_NNS in_IN myocardial_NN oxygen_NN
        consumption_NN reflected_VBD the_DT changes_NNS in_IN peak_NN intracellular_NN
        calcium_NN ,_, in_IN that_DT there_EX were_VBD minimal_JJ changes_NNS between_IN 1_CD ._. 5_CD and_CC
        2_CD ._. 5_CD mM_NN perfusate_NN calcium_NN ,_, and_CC myocardial_NN oxygen_NN consumption_NN
        was_VBD not_RB significantly_RB different_JJ between_IN perfusate_NN calcium_NN
        3_CD ._. 5_CD mM_NN and_CC dobutamine_NN (_( Figure_NN 1_CD C_NNP )_) ._. Thus_RB ,_, the_DT ratio_NN of_IN
        developed_VBN pressure_NN to_TO myocardial_NN oxygen_NN consumption_NN ,_, an_DT
        index_NN of_IN economy_NN of_IN contraction_NN ,_, significantly_RB increased_VBN
        between_IN 1_CD ._. 5_CD and_CC 2_CD ._. 5_CD mM_NN perfusate_NN calcium_NN and_CC was_VBD
        significantly_RB higher_JJR with_IN dobutamine_NN compared_VBN to_TO high_JJ
        perfusate_NN calcium_NN (_( Figure_NN 1_CD D_NNP )_) ._.
        To_TO further_VB explore_VB the_DT differences_NNS between_IN dobutamine_NN
        and_CC high_JJ calcium_NN positive_JJ inotropy_NN ,_, analysis_NN of_IN pressure_NN
        and_CC calcium_NN transient_JJ waveforms_NNS and_CC phase-plane_JJ plots_NNS
        relating_VBG pressure_NN to_TO calcium_NN was_VBD performed_VBN ._. Pressure_NN
        waveforms_NNS were_VBD significantly_RB abbreviated_JJ with_IN dobutamine_NN
        compared_VBN to_TO high_JJ perfusate_NN calcium_NN (_( total_JJ waveform_NN
        duration_NN :_: 100_CD ±_NN 15_CD vs_NNS 125_CD ±_NN 0_CD ms_NNS ,_, p_NN <_NN 0_CD ._. 01_CD )_) ._. The_DT time_NN
        from_IN onset_NN of_IN the_DT pressure_NN waveform_NN to_TO peak_VB pressure_NN was_VBD
        not_RB significantly_RB different_JJ between_IN dobutamine_NN and_CC high_JJ
        calcium_NN (_( 45_CD ±_NN 3_CD vs_NNS 52_CD ±_NN 7_CD ms_NNS ,_, p_NN =_SYM NS_NNP )_) ,_, though_IN the_DT time_NN from_IN
        peak_NN pressure_NN to_TO fall_VB to_TO baseline_NN was_VBD significantly_RB shorter_JJR
        with_IN dobutamine_NN compared_VBN to_TO high_JJ calcium_NN (_( 55_CD ±_NN 12_CD vs_NNS 73_CD ±_NN 7_CD
        ms_NNS ,_, p_NN <_NN 0_CD ._. 05_CD )_) ._. An_DT example_NN of_IN a_DT normalized_JJ pressure_NN
        waveform_NN is_VBZ shown_VBN in_IN Figure_NN 2_CD ._. No_DT significant_JJ differences_NNS
        were_VBD seen_VBN with_IN calcium_NN transient_JJ durations_NNS at_IN any_DT level_NN of_IN
        perfusate_NN calcium_NN or_CC dobutamine_NN (_( examples_NNS Figure_NN 3_CD A_DT ,_, Band_NNP
        3_CD C_NNP )_) ._. Total_JJ transient_JJ duration_NN at_IN 3_CD ._. 5_CD mM_NN perfusate_NN calcium_NN
        was_VBD 106_CD ±_NN 20_CD ms_NNS and_CC with_IN dobutamine_NN was_VBD 93_CD ±_NN 22_CD ms_NNS (_( p_NN =_SYM NS_NNP )_) ,_,
        and_CC there_EX was_VBD also_RB no_DT significant_JJ difference_NN in_IN the_DT time_NN
        from_IN onset_NN of_IN the_DT transient_JJ to_TO peak_VB (_( 3_CD ._. 5_LS mM_NN perfusate_NN
        calcium_NN 33_CD ±_NN 8_CD vs_NNS dobutamine_NN 38_CD ±_NN 14_CD ms_NNS ,_, p_NN =_SYM NS_NNP )_) ,_, or_CC
        difference_NN in_IN the_DT duration_NN between_IN the_DT peak_NN of_IN the_DT
        transient_JJ to_TO return_VB to_TO baseline_NN (_( 3_CD ._. 5_LS mM_NN perfusate_NN calcium_NN
        72_CD ±_NN 25_CD vs_NNS dobutamine_NN 60_CD ±_NN 25_CD ms_NNS ,_, p_NN =_SYM NS_NNP )_) ._. Phase-plane_NNP plots_NNS
        illustrate_VBP that_IN high_JJ perfusate_NN calcium_NN results_NNS in_IN a_DT similar_JJ
        increase_NN in_IN intracellular_NN calcium_NN compared_VBN to_TO dobutamine_NN
        though_IN relatively_RB smaller_JJR increase_NN in_IN pressure_NN (_( Figure_NN
        3_CD D_NNP ,_, E_NNP ,_, and_CC 3_CD F_NN )_) ._. Thus_RB ,_, the_DT ratio_NN of_IN pressure_NN to_TO calcium_NN at_IN
        the_DT point_NN of_IN peak_NN systolic_JJ pressure_NN is_VBZ significantly_RB higher_JJR
        with_IN dobutamine_NN compared_VBN to_TO high_JJ perfusate_NN calcium_NN (_( 0_CD ._. 103_CD ±_NN
        0_CD ._. 009_CD vs_NNS 0_CD ._. 081_CD ±_NN 0_CD ._. 012_CD mmHg_NN /_NN nM_NN ,_, p_NN <_NN 0_CD ._. 05_CD ,_, Figure_NN 4_LS )_) ._. The_DT
        increase_NN in_IN the_NNP '_POS dynamic_JJ trajectory_NN '_'' of_IN the_DT phase-plane_JJ
        plot_NN between_IN peak_NN calcium_NN and_CC peak_NN pressure_NN may_MD relate_VB to_TO
        underlying_VBG changes_NNS in_IN the_DT steady-state_JJ force-calcium_JJ
        relationship_NN as_IN proposed_VBN by_IN Hunter_NNP [_NN 10_CD ]_NN ._.
        The_DT specific_JJ protein_NN kinase_NN C_NNP inhibitor_NN chelerythrine_NN
        significantly_RB inhibited_VBD high_JJ calcium_NN positive_JJ inotropy_NN (_( 2_CD ._. 5_LS
        to_TO 3_CD ._. 5_CD mM_NN ,_, p_NN <_NN 0_CD ._. 05_CD )_) ,_, though_IN had_VBD no_DT effects_NNS on_IN
        dobutamine_NN ,_, or_CC with_IN lower_JJR levels_NNS of_IN perfusate_NN calcium_NN (_( 1_CD ._. 5_LS
        to_TO 2_CD ._. 5_CD mM_NN )_) (_( Figure_NN 5_CD A_DT )_) ._. The_DT effects_NNS of_IN chelerythrine_NN were_VBD
        mediated_JJ through_IN preventing_VBG the_DT expected_VBN increase_NN in_IN
        systolic_JJ and_CC diastolic_JJ intracellular_NN calcium_NN (_( figure_NN 5_CD B_NNP )_) ._.
        The_DT difference_NN in_IN myocardial_NN oxygen_NN consumption_NN between_IN 2_CD ._. 5_CD
        and_CC 3_CD ._. 5_CD mM_NN perfusate_NN calcium_NN was_VBD significantly_RB reduced_VBN with_IN
        the_DT addition_NN of_IN chelerythrine_NN (_( Δ_NN 2_CD ._. 5_CD to_TO 3_CD ._. 5_CD mM_NN alone_RB :_: 9_CD ._. 1_CD ±_NN
        2_CD ._. 8_CD vs_NNS Δ_NN 2_CD ._. 5_CD to_TO 3_CD ._. 5_CD mM_NN +_NN chelerythrine_NN :_: 5_CD ._. 4_CD ±_NN 1_CD ._. 2_CD
        μmoles_NNS /_NN min_NN /_NN g_SYM dry_JJ wt_NN ._. ,_, p_NN <_NN 0_CD ._. 05_CD )_) ._. Also_RB ,_, chelerythrine_NN had_VBD
        no_DT significant_JJ effects_NNS on_IN developed_VBN pressures_NNS at_IN a_DT constant_JJ
        perfusate_NN calcium_NN of_IN 2_CD ._. 5_CD mM_NN (_( 53_CD ±_NN 9_CD to_TO 50_CD ±_NN 10_CD mmHg_NN ,_,
        p_NN =_SYM NS_NNP )_) ._.
      
      
        Discussion_NNP
        
          Measurement_NNP of_IN intracellular_NN calcium_NN and_CC myocardial_NN
          oxygen_NN consumption_NN in_IN the_DT perfused_JJ mouse_NN heart_NN
          Isolated_NNP perfused_JJ mouse_NN heart_NN measurements_NNS of_IN
          intracellular_NN calcium_NN and_CC energetics_NNS have_VBP been_VBN performed_VBN
          using_VBG other_JJ methods_NNS by_IN other_JJ investigators_NNS [_NN 17_CD 18_CD ]_NN ._.
          The_DT unique_JJ aspects_NNS of_IN the_DT present_JJ study_NN are_VBP that_IN we_PRP use_VBP
          the_DT calcium_NN sensitive_JJ fluorescent_NN dye_NN rhod-_NN 2_CD to_TO measure_VB
          intracellular_NN calcium_NN [_NN 6_CD 7_CD ]_NN ,_, and_CC that_IN we_PRP have_VBP related_VBN
          these_DT measurements_NNS to_TO both_DT myocardial_NN oxygen_NN consumption_NN
          and_CC developed_VBN pressure_NN ._. An_DT appreciation_NN of_IN the_DT strengths_NNS
          and_CC limitations_NNS of_IN these_DT techniques_NNS is_VBZ required_VBN to_TO
          critically_RB evaluate_VB the_DT results_NNS ._. For_IN instance_NN ,_,
          measurements_NNS of_IN intracellular_NN calcium_NN are_VBP taken_VBN from_IN the_DT
          outer_JJ layers_NNS of_IN the_DT left_NN ventricular_NN free_JJ wall_NN ,_, though_IN
          our_PRP$ measurements_NNS of_IN myocardial_NN oxygen_NN consumption_NN and_CC
          developed_VBN pressures_NNS are_VBP global_JJ measurements_NNS ._. Differences_NNS
          between_IN the_DT epicardium_NN and_CC endocardium_NN have_VBP been_VBN
          described_VBN [_NN 19_CD ]_NN and_CC our_PRP$ measurements_NNS of_IN intracellular_NN
          calcium_NN do_VBP not_RB take_VB this_DT into_IN account_NN ,_, and_CC regional_JJ
          differences_NNS in_IN myocardial_NN strains_NNS and_CC oxygen_NN consumption_NN
          are_VBP also_RB not_RB accounted_VBD for_IN ._. However_RB ,_, one_CD advantage_NN of_IN
          using_VBG rhod-_NN 2_CD is_VBZ that_IN its_PRP$ long_JJ excitation_NN and_CC emission_NN
          wavelengths_NNS relative_JJ to_TO other_JJ calcium_NN sensitive_JJ dyes_NNS
          results_NNS in_IN minimal_JJ filtering_VBG of_IN excitation_NN and_CC emission_NN
          light_NN and_CC autofluorescence_NN [_NN 7_CD 20_CD ]_NN ._. At_IN these_DT visible_JJ
          range_NN wavelengths_NNS light_NN may_MD penetrate_VB between_IN 0_CD ._. 3_CD and_CC 0_CD ._. 4_CD
          mm_NN into_IN the_DT myocardium_NN [_NN 21_CD ]_NN which_WDT may_MD be_VB significantly_RB
          deeper_JJR than_IN shorter_JJR wavelength_NN dyes_NNS ._. This_DT is_VBZ
          approximately_RB 50_CD %_NN of_IN the_DT total_JJ wall_NN thickness_NN in_IN the_DT
          mouse_NN [_NN 22_CD ]_NN ,_, and_CC thus_RB our_PRP$ measurements_NNS are_VBP from_IN the_DT
          outer_JJ 50_CD %_NN of_IN the_DT myocardium_NN ._.
          Measurements_NNP of_IN intracellular_NN calcium_NN and_CC myocardial_NN
          oxygen_NN consumption_NN have_VBP been_VBN performed_VBN in_IN different_JJ
          hearts_NNS due_JJ to_TO the_DT difficulty_NN in_IN obtaining_VBG these_DT
          measurements_NNS in_IN a_DT single_JJ experiment_NN ,_, and_CC this_DT may_MD
          introduce_VB variability_NN into_IN the_DT results_NNS ._. We_PRP have_VBP also_RB
          performed_VBN only_RB 2_CD interventions_NNS per_IN heart_NN ._. The_DT time_NN taken_VBN
          to_TO obtain_VB stable_JJ measurements_NNS of_IN effluent_JJ oxygen_NN
          saturations_NNS used_VBN in_IN the_DT calculation_NN of_IN myocardial_NN oxygen_NN
          consumption_NN is_VBZ approximately_RB 30_CD minutes_NNS and_CC the_DT mouse_NN
          heart_NN preparation_NN is_VBZ usually_RB not_RB stable_JJ beyond_IN 80_CD
          minutes_NNS ,_, so_IN that_IN only_RB 2_CD interventions_NNS can_MD be_VB obtained_VBN ._.
          Furthermore_RB ,_, when_WRB comparing_VBG different_JJ inotropes_NNS such_JJ as_IN
          high_JJ calcium_NN and_CC dobutamine_NN ,_, it_PRP is_VBZ desirable_JJ not_RB to_TO use_VB
          the_DT same_JJ heart_NN ._. As_IN we_PRP have_VBP postulated_JJ that_IN different_JJ
          signaling_VBG pathways_NNS may_MD be_VB activated_VBN by_IN these_DT inotropes_NNS ,_,
          serially_RB administering_VBG these_DT to_TO a_DT single_JJ heart_NN may_MD result_VB
          in_IN persistent_JJ activation_NN of_IN a_DT protein_NN kinase_NN even_RB after_IN
          washout_NN of_IN that_DT agent_NN ._.
          Coronary_NNP flow_NN does_VBZ not_RB increase_VB with_IN inotropes_NNS in_IN this_DT
          study_NN ,_, though_IN other_JJ studies_NNS with_IN perfused_JJ mouse_NN hearts_NNS
          have_VBP shown_VBN an_DT increase_NN [_NN 23_CD ]_NN ._. The_DT reason_NN for_IN this_DT is_VBZ
          unclear_JJ ,_, though_IN oxygen_NN delivery_NN to_TO the_DT heart_NN is_VBZ not_RB
          compromised_VBN ._. We_PRP have_VBP the_DT advantage_NN with_IN the_DT use_NN of_IN the_DT
          absorbance_NN spectrum_NN between_IN 500_CD and_CC 600_CD nm_NN ,_, used_VBN in_IN the_DT
          calculation_NN of_IN intracellular_NN calcium_NN ,_, that_IN this_DT is_VBZ also_RB
          sensitive_JJ to_TO the_DT presence_NN of_IN deoxy-_NN or_CC oxygenated_JJ
          myoglobin_NN [_NN 7_CD ]_NN ._. With_IN our_PRP$ technique_NN the_DT myoglobin_NN
          spectrum_NN is_VBZ invariably_RB consistent_JJ with_IN full_JJ oxygenation_NN
          and_CC any_DT (_( rare_JJ )_) hearts_NNS that_WDT do_VBP not_RB show_VB this_DT pattern_NN are_VBP
          discarded_VBN ._. By_IN using_VBG physiological_JJ heart_NN rates_NNS and_CC
          temperatures_NNS we_PRP have_VBP attempted_VBN to_TO reproduce_VB normal_JJ murine_NN
          physiological_JJ conditions_NNS ._. As_IN the_DT mouse_NN heart_NN has_VBZ a_DT
          negative_JJ force-frequency_JJ response_NN at_IN physiological_JJ heart_NN
          rates_NNS [_NN 24_CD ]_NN ,_, developed_VBN pressures_NNS in_IN our_PRP$ studies_NNS are_VBP
          lower_JJR than_IN might_MD be_VB expected_VBN with_IN lower_JJR heart_NN rates_NNS ._.
          Nevertheless_RB ,_, the_DT developed_VBN pressures_NNS in_IN this_DT study_NN are_VBP
          quite_RB consistent_JJ with_IN other_JJ studies_NNS [_NN 17_CD 24_CD 25_CD ]_NN ._. That_DT
          pressures_NNS in_IN perfused_JJ mouse_NN heart_NN studies_NNS are_VBP generally_RB
          low_JJ may_MD relate_VB to_TO the_DT resistance_NN of_IN the_DT murine_NN myocardium_NN
          to_TO extracellular_NN calcium_NN [_NN 26_CD ]_NN ._. Diastolic_NNP calcium_NN
          levels_NNS are_VBP relatively_RB high_JJ with_IN this_DT method_NN especially_RB
          with_IN dobutamine_NN or_CC 3_CD ._. 5_CD mM_NN perfusate_NN calcium_NN (_( table_NN 1_LS )_) ._.
          This_DT appears_VBZ at_IN least_JJS in_IN part_NN related_VBN to_TO the_DT limited_JJ
          sampling_VBG of_IN 8_CD time_NN points_NNS per_IN beat_NN in_IN the_DT current_JJ paper_NN ,_,
          and_CC may_MD also_RB relate_VB to_TO motion_NN artifact_NN associated_VBN with_IN
          the_DT positive_JJ inotropes_NNS ._. These_DT limitations_NNS are_VBP especially_RB
          prominent_JJ in_IN the_DT small_JJ and_CC rapid_JJ beating_NN mouse_NN heart_NN ._.
          Recently_RB ,_, improved_VBN analogue_NN to_TO digital_JJ capabilities_NNS and_CC
          software_NN acquisition_NN has_VBZ significantly_RB improved_VBN our_PRP$
          ability_NN to_TO record_VB many_JJ more_JJR time_NN points_NNS during_IN the_DT
          cardiac_JJ cycle_NN ,_, and_CC with_IN this_DT we_PRP have_VBP noted_VBN slightly_RB
          higher_JJR differences_NNS between_IN peak_NN and_CC diastolic_JJ calcium_NN
          levels_NNS (_( MacGowan_NNP and_CC Koretsky_NNP ,_, unpublished_JJ data_NNS )_) ._. It_PRP
          appears_VBZ unlikely_JJ that_IN this_DT is_VBZ related_VBN to_TO a_DT calcium_NN
          overload_NN state_NN as_IN diastolic_JJ pressures_NNS do_VBP not_RB rise_VB with_IN
          high_JJ perfusate_NN calcium_NN or_CC dobutamine_NN ,_, and_CC pressure_NN
          waveforms_NNS abbreviate_NN with_IN dobutamine_NN ._.
        
      
      
        Conclusions_NNP
        In_IN the_DT perfused_JJ mouse_NN heart_NN ,_, high_JJ perfusate_NN calcium_NN
        positive_JJ inotropy_NN compared_VBN to_TO dobutamine_NN results_NNS in_IN reduced_VBN
        myofilament_NN calcium_NN responsiveness_NNS ,_, decreased_VBD energetic_JJ
        efficiency_NN and_CC is_VBZ dependent_JJ in_IN part_NN on_IN protein_NN kinase_NN C_NNP
        activation_NN ._. It_PRP must_MD be_VB recognized_VBN that_IN agents_NNS that_WDT increase_NN
        the_DT amplitude_NN of_IN the_DT calcium_NN transient_JJ through_IN activation_NN
        of_IN protein_NN kinase_NN A_DT ,_, such_JJ as_IN phosphodiesterase_NN inhibitors_NNS
        are_VBP associated_VBN with_IN adverse_JJ outcomes_NNS in_IN congestive_JJ heart_NN
        failure_NN patients_NNS [_NN 27_CD ]_NN ,_, and_CC so_RB our_PRP$ findings_NNS with_IN
        dobutamine_NN are_VBP unlikely_JJ to_TO translate_VB into_IN clinical_JJ benefit_NN ._.
        Nevertheless_RB ,_, these_DT results_NNS illustrate_VBP the_DT importance_NN of_IN
        calcium_NN handling_VBG in_IN the_DT energetic_JJ efficiency_NN of_IN an_DT
        inotrope_NN ,_, and_CC these_DT methods_NNS will_MD be_VB useful_JJ in_IN studying_VBG
        genetically_RB engineered_VBN mouse_NN models_NNS with_IN altered_VBN
        myofilament_NN calcium_NN responsiveness_NNS ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          The_DT isolated_VBN perfused_JJ mouse_NN heart_NN and_CC myocardial_NN
          oxygen_NN consumption_NN
          Experiments_NNS were_VBD performed_VBN in_IN 2_CD groups_NNS ._. In_IN one_CD group_NN ,_,
          developed_VBN pressure_NN and_CC myocardial_NN oxygen_NN consumption_NN were_VBD
          measured_VBN in_IN the_DT perfused_JJ mouse_NN heart_NN ._. In_IN another_DT group_NN of_IN
          perfused_JJ hearts_NNS intracellular_NN calcium_NN and_CC developed_VBN
          pressure_NN were_VBD measured_VBN ._. Male_NN mice_NNS (_( 129_CD /_NN SV_NNP ter_NN strain_NN ,_,
          mean_VB weight_NN 26_CD ._. 9_CD ±_NN 2_CD ._. 6_CD g_SYM )_) were_VBD used_VBN ._. Anesthesia_NNP was_VBD
          induced_VBN with_IN 1_CD ._. 5_CD to_TO 3_CD ._. 0_CD mg_NN of_IN intraperitoneal_NN
          pentobarbital_NN sodium_NN ,_, and_CC the_DT animal_NN was_VBD anticoagulated_JJ
          with_IN 100_CD units_NNS of_IN heparin_NN ._. The_DT heart_NN was_VBD removed_VBN from_IN the_DT
          chest_NN and_CC the_DT aorta_NN was_VBD cannulated_JJ with_IN a_DT 23_CD gauge_NN
          needle_NN ._. Retrograde_NNP coronary_JJ perfusion_NN at_IN a_DT constant_JJ
          perfusion_NN pressure_NN of_IN 55_CD mmHg_NN with_IN oxygenated_JJ modified_VBN
          Krebs_NNP solution_NN was_VBD started_VBN ._. The_DT Kreb_NNP 's_POS solution_NN consisted_VBD
          of_IN (_( mM_NN )_) :_: NaCl_NNP 112_CD ,_, KCl_NNP 4_CD ._. 7_CD ,_, MgSO_NNP 
          4_CD 1_CD ._. 2_CD ,_, Na-_NNP EDTA_NNP 0_CD ._. 5_CD ,_, NaHCO_NNP 
          3_CD 28_CD ._. 0_CD ,_, Glucose_NNP 5_CD ._. 5_CD ,_, Pyruvate_NNP 5_CD ._. 0_CD ,_,
          CaCl_NNP 
          2_CD 2_CD ._. 5_CD ,_, 50_CD μM_NN octanoate_NN ,_, and_CC pH_NN was_VBD
          adjusted_VBN to_TO 7_CD ._. 4_CD ._. For_IN some_DT studies_VBZ the_DT concentration_NN of_IN
          calcium_NN was_VBD varied_VBN to_TO produce_VB an_DT inotropic_JJ effect_NN ._. The_DT
          concentration_NN of_IN NaCl_NNP was_VBD adjusted_VBN accordingly_RB for_IN these_DT
          experiments_NNS to_TO maintain_VB osmolality_NN ._. To_TO eliminate_VB the_DT
          effects_NNS of_IN cathecholamine_NN release_NN by_IN pacing_NN esmolol_NN (_( 0_CD ._. 1_LS
          μM_NN )_) (_( Du_NNP Pont_NNP ,_, Wilmington_NNP ,_, DE_NNP )_) was_VBD added_VBN to_TO the_DT perfusate_NN ._.
          The_DT temperature_NN of_IN the_DT perfusate_NN entering_VBG the_DT heart_NN was_VBD
          set_VBN at_IN 37_CD °_NN C_NNP ._. Flow_NNP was_VBD monitored_VBN with_IN a_DT glass_NN flow_NN meter_NN ._.
          A_DT rubber_NN latex_NN balloon_NN on_IN the_DT end_NN of_IN a_DT plastic_NN cannula_NN ,_,
          was_VBD inserted_VBN into_IN the_DT left_NN ventricle_NN through_IN an_DT incision_NN
          in_IN the_DT left_NN atrium_NN ._. This_DT was_VBD then_RB connected_VBN to_TO a_DT Gould_NNP
          pressure_NN recorder_NN (_( Gould_NNP ,_, Cleveland_NNP ,_, Ohio_NNP )_) for_IN
          measurement_NN of_IN left_JJ ventricular_NN pressure_NN ._. The_DT left_VBN
          ventricular_NN diastolic_JJ pressure_NN was_VBD set_VBN at_IN 0_CD -_: 5_CD mm_NN Hg_NNP
          using_VBG a_DT micro-syringe_JJ ._. Hearts_NNPS were_VBD paced_VBN at_IN 8_CD Hz_NNP which_WDT is_VBZ
          physiological_JJ heart_NN rate_NN for_IN the_DT mouse_NN ,_, using_VBG a_DT
          stimulator_NN with_IN one_CD lead_VB inserted_VBN into_IN the_DT right_JJ
          ventricle_NN and_CC the_DT other_JJ adjacent_JJ to_TO the_DT epicardium_NN ._. In_IN
          the_DT myocardial_NN oxygen_NN consumption_NN experiments_NNS ,_, the_DT
          perfused_JJ mouse_NN heart_NN was_VBD placed_VBN in_IN a_DT glass_NN ,_, water_NN
          jacketed_JJ chamber_NN ,_, which_WDT was_VBD sealed_VBN at_IN the_DT top_NN ._. Myocardial_NNP
          oxygen_NN consumption_NN was_VBD determined_VBN from_IN influent_NN and_CC
          effluent_JJ oxygen_NN content_NN (_( measured_VBN by_IN blood_NN gas_NN analyzer_NN ,_,
          ABL-_NNP 30_CD ,_, Copenhagen_NNP ,_, Denmark_NNP )_) and_CC flow_NN rate_NN ._.
        
        
          Measurement_NNP of_IN Intracellular_NNP Calcium_NNP
          The_DT methods_NNS used_VBN to_TO measure_VB intracellular_NN calcium_NN with_IN
          rhod-_NN 2_CD in_IN perfused_JJ hearts_NNS have_VBP been_VBN previously_RB
          extensively_RB described_VBD [_NN 6_CD 7_CD 20_CD ]_NN ._. Rhod-_NNP 2_CD (_( Molecular_NNP
          Probes_NNP ,_, OR_NNP ,_, 100_CD μg_NN )_) was_VBD dissolved_VBN with_IN dimethylsulfoxide_NN
          (_( DMSO_NNP ,_, 4_CD μL_NN )_) and_CC dH_NN 
          2_CD O_NNP (_( 200_CD μL_NN )_) ,_, and_CC loaded_VBD through_IN the_DT
          coronary_JJ perfusate_NN ._. After_IN the_DT washout_NN period_NN serial_NN
          measurements_NNS of_IN fluorescence_NN alternating_VBG with_IN absorbance_NN
          were_VBD taken_VBN ._. Fluorescence_NNP scans_NNS were_VBD taken_VBN at_IN high_JJ time_NN
          resolution_NN to_TO allow_VB quantification_NN of_IN changes_NNS in_IN
          fluorescence_NN during_IN the_DT cardiac_JJ cycle_NN ._. Excitation_NNP at_IN 524_CD
          nm_NN and_CC emission_NN at_IN 589_CD nm_NN was_VBD used_VBN for_IN fluorescence_NN
          measurements_NNS ._.
          Quantification_NNP of_IN the_DT relative_JJ amount_NN of_IN rhod-_NN 2_CD in_IN the_DT
          heart_NN using_VBG absorbance_NN measurements_NNS ,_, was_VBD done_VBN by_IN taking_VBG
          the_DT ratio_NN of_IN absorbance_NN at_IN 524_CD nm_NN (_( rhod-_NN 2_CD sensitive_JJ )_) to_TO
          589_CD nm_NN (_( rhod-_NN 2_CD insensitive_JJ )_) which_WDT eliminated_VBD the_DT effect_NN
          of_IN motion_NN as_IN both_DT wavelengths_NNS would_MD be_VB equally_RB affected_VBN
          by_IN motion_NN ,_, though_IN only_RB 524_CD reflected_VBD the_DT concentration_NN of_IN
          rhod-_NN 2_CD [_NN 7_CD ]_NN ._. These_DT wavelengths_NNS (_( 524_CD ,_, 589_CD nm_NN )_) were_VBD
          chosen_VBN as_IN these_DT were_VBD isosbestic_JJ points_NNS not_RB effected_JJ by_IN
          changes_NNS in_IN absorbance_NN of_IN myoglobin_NN induced_VBN by_IN oxygen_NN
          desaturation_NN [_NN 7_CD ]_NN ._. In_IN solution_NN maximal_NN rhod-_NN 2_CD
          absorbance_NN is_VBZ at_IN 554_CD nm_NN ._. However_RB ,_, this_DT wavelength_NN is_VBZ
          effected_JJ by_IN changes_NNS in_IN oxygen_NN saturation_NN ,_, the_DT relative_JJ
          absorbance_NN compared_VBN to_TO 524_CD nm_NN is_VBZ decreased_VBN due_JJ to_TO inner_JJ
          filter_NN effects_NNS and_CC it_PRP does_VBZ not_RB adequately_RB correct_JJ for_IN
          changes_NNS in_IN scattering_VBG [_NN 7_CD ]_NN ._. Dye_NNP absorbance_NN (_( A_DT 
          rhod_NN 2_LS )_) was_VBD calculated_VBN according_VBG to_TO
          the_DT formula_NN :_:
          A_DT 
          rhod_NN 2_CD =_SYM log_VB {_( (_( R_NN 
          524_CD /_NN R_NN 
          589_CD )_) 
          0_CD (_( R_NN 
          524_CD /_NN R_NN 
          589_CD )_) 
          rhod_NN 2_LS }_)     (_( 1_LS )_)
          where_WRB R_NN 
          524_CD is_VBZ the_DT reflectance_NN intensity_NN at_IN
          the_DT rhod-_NN 2_CD sensitive_JJ point_NN of_IN 524_CD nm_NN ,_, and_CC R_NN 
          589_CD is_VBZ the_DT rhod-_NN 2_CD insensitive_JJ point_NN ,_,
          before_IN (_( )_) 
          0_CD and_CC after_IN (_( )_) 
          rhod_NN 2_CD loading_NN ._.
          At_IN the_DT end_NN of_IN the_DT perfusion_NN protocol_NN ,_, maximal_NN
          fluorescence_NN ,_, used_VBN in_IN the_DT calculation_NN of_IN [_NN Ca_MD 2_CD +_NN ]_NN i_NNP was_VBD
          determined_VBN by_IN tetanizing_VBG the_DT heart_NN with_IN a_DT bolus_JJ of_IN
          calcium_NN chloride_NN (_( 20_CD mM_NN )_) without_IN any_DT energy_NN substrate_NN ,_,
          and_CC with_IN cyclopiazonic_JJ acid_NN (_( Sigma_NNP Chemical_NNP Co_NNP ._. ,_, 10_CD μM_NN )_) ,_,
          which_WDT is_VBZ a_DT potent_JJ inhibitor_NN of_IN Ca_MD 2_CD +_NN -_: ATPase_NNP and_CC thus_RB
          blocks_VBZ calcium_NN uptake_NN by_IN the_DT sarcoplasmic_JJ reticulum_NN [_NN 28_CD
          ]_NN ._. Fluorescence_NNP and_CC pressure_NN were_VBD monitored_VBN
          continuously_RB ,_, and_CC the_DT point_NN of_IN maximal_NN fluorescence_NN was_VBD
          taken_VBN as_IN the_DT point_NN were_VBD pressure_NN stabilized_VBN at_IN a_DT steady_JJ
          state_NN ._. To_TO account_VB for_IN changes_NNS in_IN light_JJ scattering_VBG
          properties_NNS from_IN the_DT heart_NN during_IN tetanization_NN ,_, the_DT
          maximal_NN fluorescence_NN was_VBD corrected_VBN by_IN multiplying_VBG by_IN the_DT
          ratio_NN of_IN R_NN 
          524_CD pre-tetanization_JJ to_TO R_NN 
          524_CD during_IN tetanization_NN [_NN 7_CD ]_NN ._.
          Intracellular_NNP calcium_NN was_VBD calculated_VBN using_VBG the_DT
          formula_NN :_:
          [_NN Ca_MD 2_CD +_NN ]_NN i_NNP =_SYM K_NNP 
          d_SYM (_( F_NN 
          t_NN -_: F_NN 
          o_NN )_) /_NN (_( F_NN 
          max_NN -_: F_NN 
          t_NN )_)     (_( 2_LS )_)
          where_WRB K_NNP 
          d_SYM is_VBZ the_DT dissociation_NN constant_JJ for_IN
          rhod-_NN 2_CD and_CC calcium_NN (_( determined_VBN by_IN in-vitro_JJ calibration_NN
          with_IN rhod-_NN 2_CD and_CC myoglobin_NN by_IN del_FW Nido_NNP et_CC al_NN ,_, ref_NN [_NN 20_CD ]_NN ,_,
          and_CC confirmed_VBN by_IN in-vivo_JJ manganese_NN quenching_VBG ,_, ref_NN [_NN 29_CD ]_NN
          )_) and_CC is_VBZ 710_CD nM_NN ,_, F_NN 
          t_NN =_SYM fluorescence_NN at_IN time_NN t_NN ,_, F_NN 
          max_NN =_SYM maximal_NN fluorescence_NN from_IN
          tetanized_JJ heart_NN ,_, and_CC the_DT fluorescence_NN from_IN the_DT heart_NN
          assuming_VBG rhod-_NN 2_CD had_VBD no_DT calcium_NN bound_VBN is_VBZ given_VBN by_IN F_NN 
          0_CD =_SYM F_NN 
          b_SYM +_NN 
          a_DT (_( F_NN 
          max_NN -_: F_NN 
          b_SYM )_) ,_, where_WRB F_NN 
          b_SYM is_VBZ the_DT background_NN counts_VBZ from_IN the_DT
          heart_NN prior_RB to_TO dye_NN loading_NN ,_, and_CC 
          a_DT =_SYM rhod-_NN 2_CD fluorescence_NN in_IN the_DT
          absence_NN of_IN calcium_NN /_NN rhod-_NN 2_CD fluorescence_NN in_IN the_DT presence_NN
          of_IN saturating_VBG calcium_NN ._. For_IN rhod-_NN 2_CD the_DT value_NN of_IN 
          a_DT is_VBZ approximately_RB 0_CD ,_, thus_RB for_IN
          rhod-_NN 2_CD ,_, F_NN 
          0_CD was_VBD assumed_VBN to_TO be_VB equal_JJ to_TO F_NN 
          b_SYM ._.
          To_TO account_VB for_IN changes_NNS in_IN dye_NN concentration_NN ,_, formula_NN 2_CD
          needs_VBZ to_TO be_VB modified_VBN to_TO account_VB for_IN changes_NNS in_IN absorbance_NN
          (_( A_DT 
          rhod-_NN 2_CD ,_, formula_NN 1_LS )_) due_JJ to_TO dye_NN
          leakage_NN ._.
          [_NN Ca_MD 2_CD +_NN ]_NN i_NNP =_SYM K_NNP 
          d_SYM (_( (_( F_NN 
          t_NN -_: F_NN 
          o_NN )_) /_NN At_IN )_) /_NN (_( (_( (_( F_NN 
          max_NN -_: F_NN 
          o_NN )_) /_NN A_DT 
          max_NN )_) -_: (_( (_( F_NN 
          t_NN -_: F_NN 
          o_NN )_) /_NN A_DT 
          t_NN )_) )_) (_( 3_LS )_)    
          where_WRB A_DT 
          t_NN =_SYM dye_NN absorbance_NN at_IN time_NN t_NN ,_, A_DT 
          max_NN is_VBZ dye_NN absorbance_NN just_RB prior_RB to_TO
          tetanizing_VBG the_DT heart_NN ._. A_DT 
          max_NN is_VBZ not_RB determined_VBN when_WRB heart_NN has_VBZ
          tetanized_JJ because_IN of_IN the_DT marked_VBN influence_NN of_IN the_DT shape_NN
          change_NN and_CC desaturation_NN of_IN myoglobin_NN on_IN the_DT reflectance_NN
          spectrum_NN ._.
        
        
          Interventions_NNP
          For_IN each_DT heart_NN only_RB a_DT baseline_NN and_CC one_CD intervention_NN
          was_VBD used_VBN ,_, and_CC N_NNP =_SYM 4_CD -_: 6_CD for_IN all_DT groups_NNS ._. The_DT time_NN to_TO achieve_VB
          a_DT stable_JJ state_NN (_( particularly_RB with_IN respect_NN to_TO effluent_JJ PO_NNP 
          2_CD concentrations_NNS )_) or_CC load_NN rhod-_NN 2_CD ,_, and_CC
          then_RB acquire_VB baseline_NN data_NNS and_CC perform_VB 1_CD intervention_NN is_VBZ
          60_CD -_: 90_CD minutes_NNS ,_, beyond_IN which_WDT the_DT preparation_NN is_VBZ not_RB stable_JJ
          and_CC so_RB more_JJR than_IN 1_CD intervention_NN per_IN mouse_NN heart_NN was_VBD not_RB
          undertaken_VBN ._. In_IN the_DT developed_VBN pressure_NN /_NN oxygen_NN consumption_NN
          experiments_NNS ,_, the_DT following_VBG interventions_NNS were_VBD used_VBN :_: 1_LS )_)
          varying_VBG perfusate_NN calcium_NN from_IN baseline_NN 2_CD ._. 5_CD mM_NN to_TO 3_CD ._. 5_CD ;_: 2_LS )_)
          baseline_NN perfusate_NN calcium_NN 1_CD ._. 5_CD mM_NN to_TO 2_CD ._. 5_CD mM_NN ;_: 3_LS )_) baseline_NN
          perfusate_NN calcium_NN 2_CD ._. 0_CD mM_NN and_CC then_RB addition_NN of_IN dobutamine_NN
          0_CD ._. 9_CD μM_NN ._. ;_: 4_LS )_) to_TO antagonize_VB the_DT effects_NNS of_IN protein_NN kinase_NN
          C_NNP ,_, the_DT specific_JJ antagonist_NN chelerythrine_NN (_( ref_NN 30_CD ;_: 10_CD nM_NN ,_,
          Calbiochem-_NNP Novabiochem_NNP Intl_NNP ,_, La_NNP Jolla_NNP ,_, CA_NNP )_) was_VBD added_VBN to_TO
          the_DT perfusate_NN when_WRB inducing_VBG positive_JJ inotropy_NN ._. In_IN all_DT of_IN
          these_DT the_DT chelerythrine_NN was_VBD added_VBN to_TO the_DT perfusate_NN
          containing_VBG the_DT higher_JJR level_NN of_IN perfusate_NN calcium_NN or_CC
          dobutamine_NN ._. This_DT dose_NN was_VBD chosen_VBN to_TO reduce_VB the_DT expected_VBN
          increase_NN in_IN pressure_NN with_IN perfusate_NN calcium_NN 3_CD ._. 5_CD mM_NN by_IN 50_CD %_NN
          after_IN dose_NN ranging_VBG studies_NNS (_( 1_CD nM_NN to_TO 1000_CD nM_NN )_) ._. In_IN addition_NN
          in_IN another_DT group_NN of_IN experiments_NNS during_IN constant_JJ infusion_NN
          of_IN perfusate_NN calcium_NN 2_CD ._. 5_CD mM_NN ,_, chelerythrine_NN was_VBD added_VBN
          without_IN changing_VBG perfusate_NN calcium_NN concentration_NN ._. In_IN all_DT
          experiments_NNS ,_, the_DT control_NN period_NN was_VBD followed_VBN by_IN the_DT
          intervention_NN ,_, and_CC repeated_VBD measurements_NNS of_IN both_DT developed_VBN
          pressure_NN and_CC myocardial_NN oxygen_NN consumption_NN were_VBD taken_VBN for_IN
          a_DT period_NN of_IN approximately_RB 30_CD minutes_NNS ._. Measurements_NNP of_IN
          intracellular_NN calcium_NN were_VBD performed_VBN 1_LS )_) at_IN perfusate_NN
          calcium_NN concentrations_NNS at_IN baseline_NN of_IN 2_CD ._. 5_CD mM_NN increasing_VBG
          to_TO 3_CD ._. 5_CD mM_NN ,_, 2_LS )_) decreasing_VBG from_IN 2_CD ._. 5_CD to_TO 1_CD ._. 5_CD mM_NN ,_, and_CC 3_LS )_) 2_CD ._. 0_CD
          mM_NN baseline_NN with_IN subsequent_JJ addition_NN of_IN dobutamine_NN 0_CD ._. 9_CD
          μM_NN ._. The_DT effects_NNS of_IN chelerythrine_NN on_IN intracellular_NN calcium_NN
          was_VBD only_RB determined_VBN for_IN those_DT interventions_NNS with_IN which_WDT
          chelerythrine_NN had_VBD significant_JJ effects_NNS on_IN myocardial_NN
          oxygen_NN consumption_NN and_CC developed_VBN pressure_NN ._.
        
        
          Data_NNP and_CC Statistical_NNP Analysis_NNP
          One_CD way_NN analysis_NN of_IN variance_NN with_IN the_DT Scheffe_NNP test_NN was_VBD
          used_VBN to_TO test_VB significance_NN of_IN differences_NNS between_IN groups_NNS ._.
          Developed_VBN pressure_NN data_NNS from_IN the_DT myocardial_NN oxygen_NN
          consumption_NN and_CC intracellular_NN calcium_NN experiments_NNS were_VBD
          combined_VBN as_IN this_DT was_VBD obtained_VBN under_IN the_DT same_JJ experimental_JJ
          conditions_NNS ._. The_DT ratio_NN of_IN developed_VBN pressure_NN to_TO myocardial_NN
          oxygen_NN consumption_NN was_VBD derived_VBN as_IN an_DT index_NN of_IN economy_NN of_IN
          contraction_NN ._. Data_NNP are_VBP expressed_VBN as_IN mean_NN ±_NN standard_JJ
          deviation_NN ._.
        
      
    
  
